Stock Price Quote

RPG LIFE SCIENCES LTD.

NSE : RPGLIFEBSE : 532983ISIN CODE : INE105J01010Industry : Pharmaceuticals & DrugsHouse : RPG Enterprises
BSE2174.7530.95 (+1.44 %)
PREV CLOSE ( ) 2143.80
OPEN PRICE ( ) 2143.80
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 369
TODAY'S LOW / HIGH ( )2143.80 2175.95
52 WK LOW / HIGH ( )1382.55 2976.7
NSE2170.2025.6 (+1.19 %)
PREV CLOSE( ) 2144.60
OPEN PRICE ( ) 2143.20
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 13713
TODAY'S LOW / HIGH( ) 2139.60 2179.00
52 WK LOW / HIGH ( )1381 2974.95
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 2007
Management Info
Harsh Goenka - Chairman Ashok Nair - Managing Director
Registered Office

Address R P G House , 463,Ceat Mahal,Dr. Annie Besant Road, Worli,
Mumbai,
Maharashtra-400030

Phone 022 - 24981650 / 24986375

Email info@rpglifesciences.com

Website www.rpglifesciences.com

Registrars Details
MUFG Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE

NEWS

29Apr Appointment of Director
Inter alia, approved:- 1. Recommended of final dividend of Rs. 20 (Rupe..
11Apr RPG Life Sciences informs about compli
RPG Life Sciences has enclosed certificate dated April 03, 2025 issued b..
08Apr RPG Life Sciences informs about change
RPG Life Sciences has informed that on the recommendation of the Nominat..
27Jan RPG Life Sciences leads the gainers of
RPG Life Sciences is currently trading at Rs. 2293.95, up by 216.55 poin..
25Jan RPG Life Sciences informs about newspa
In terms of the Regulation 30 read with Schedule III of the SEBI (Listin..

Financials

in Millions
QTR Mar 25 ANNUAL 25
Net Profit1173.51832.4
Gross Profit 1349 2328.8
Operating Profit 305.51723.3
Net Sales 1430.96534.3

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  30467.00 (0.32%)
M.Cap ( in Cr)66245.02
Medplus Health Servi (BSE)
peergroup  887.70 (8.50%)
M.Cap ( in Cr)10162.01
Divi's Lab (BSE)
peergroup  6271.40 (1.00%)
M.Cap ( in Cr)166130.24
NGL Fine-Chem (BSE)
peergroup  1265.00 (4.76%)
M.Cap ( in Cr)778.43
Jenburkt Pharma (BSE)
peergroup  1097.00 (4.50%)
M.Cap ( in Cr)463.84

Shareholding Pattern

PROMOTERS 72.95%
MUTUAL FUNDS/UTI 3.53%
NON-INSTITUTION 21.47%
FI/BANKS/INSURANCE 0.22%
GOVERNMENT 0%
FII 0%

About RPG Life Sciences Ltd.

RPG Life Sciences Ltd. was incorporated in the year 2007. Its today's share price is 2174.75. Its current market capitalisation stands at Rs 3562.01 Cr. In the latest quarter, company has reported Gross Sales of Rs. 6239.2 Cr and Total Income of Rs.5892.6 Cr. The company's management includes Manoj Maheshwari, Ashok Nair, Hiten Kotak, Rajat Bhargava, Radhika Gupta, Anil Matai, Sachin Nandgaonkar, Bhaskar Iyer, Zahabiya Khorakiwala, Harsh Goenka, Rajesh Shirambekar.

It is listed on the BSE with a BSE Code of 532983 , NSE with an NSE Symbol of RPGLIFE and ISIN of INE105J01010. It's Registered office is at R P G House , 463,Ceat Mahal,Dr. Annie Besant Road, WorliMumbai-400030, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are BSR & Co LLP, Lovelock & Lewes, SRBC & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.